We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.
One company value investors might notice is Progyny (PGNY - Free Report) . PGNY is currently sporting a Zacks Rank #2 (Buy), as well as an A grade for Value. The stock has a Forward P/E ratio of 12.02. This compares to its industry's average Forward P/E of 15.24. Over the past year, PGNY's Forward P/E has been as high as 14.50 and as low as 8.81, with a median of 12.68.
PGNY is also sporting a PEG ratio of 0.72. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. PGNY's industry has an average PEG of 1.05 right now. Over the past 52 weeks, PGNY's PEG has been as high as 0.94 and as low as 0.50, with a median of 0.78.
Investors could also keep in mind Teladoc Health (TDOC - Free Report) , another Medical Services stock with a Zacks Rank of #2 (Buy) and Value grade of A.
Teladoc Health is trading at a forward earnings multiple of -8.41 at the moment, with a PEG ratio of -0.17. This compares to its industry's average P/E of 15.24 and average PEG ratio of 1.05.
Over the last 12 months, TDOC's P/E has been as high as -1.57, as low as -15.04, with a median of -8.10, and its PEG ratio has been as high as -0.12, as low as -0.18, with a median of -0.14.
Teladoc Health sports a P/B ratio of 0.99 as well; this compares to its industry's price-to-book ratio of 1.54. In the past 52 weeks, TDOC's P/B has been as high as 1.65, as low as 0.80, with a median of 1.01.
These are just a handful of the figures considered in Progyny and Teladoc Health's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that PGNY and TDOC is an impressive value stock right now.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Progyny (PGNY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.
One company value investors might notice is Progyny (PGNY - Free Report) . PGNY is currently sporting a Zacks Rank #2 (Buy), as well as an A grade for Value. The stock has a Forward P/E ratio of 12.02. This compares to its industry's average Forward P/E of 15.24. Over the past year, PGNY's Forward P/E has been as high as 14.50 and as low as 8.81, with a median of 12.68.
PGNY is also sporting a PEG ratio of 0.72. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. PGNY's industry has an average PEG of 1.05 right now. Over the past 52 weeks, PGNY's PEG has been as high as 0.94 and as low as 0.50, with a median of 0.78.
Investors could also keep in mind Teladoc Health (TDOC - Free Report) , another Medical Services stock with a Zacks Rank of #2 (Buy) and Value grade of A.
Teladoc Health is trading at a forward earnings multiple of -8.41 at the moment, with a PEG ratio of -0.17. This compares to its industry's average P/E of 15.24 and average PEG ratio of 1.05.
Over the last 12 months, TDOC's P/E has been as high as -1.57, as low as -15.04, with a median of -8.10, and its PEG ratio has been as high as -0.12, as low as -0.18, with a median of -0.14.
Teladoc Health sports a P/B ratio of 0.99 as well; this compares to its industry's price-to-book ratio of 1.54. In the past 52 weeks, TDOC's P/B has been as high as 1.65, as low as 0.80, with a median of 1.01.
These are just a handful of the figures considered in Progyny and Teladoc Health's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that PGNY and TDOC is an impressive value stock right now.